Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.
暂无分享,去创建一个
P. Voûte | J. Ottenkamp | M. Offringa | L. Kremer | L. Kremer | L C Kremer | E C van Dalen | M Offringa | J Ottenkamp | P A Voûte | E. V. van Dalen | P. Voute | C. DalenvanE.
[1] P. Steinherz,et al. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. , 1995, Medical and pediatric oncology.
[2] S. Sallan,et al. Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukemia: a 10-year experience. , 1984, Seminars in oncology.
[3] J. Krischer,et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Levitt,et al. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] S. Swain,et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] G. Levitt,et al. Cardiac function in Wilms' tumor survivors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Mantle,et al. Anthracycline-induced cardiomyopathy in children: a report of six cases. , 1984, Medical and pediatric oncology.
[8] S. Colan,et al. Monitoring for anthracycline cardiotoxicity. , 1994, Pediatrics.
[9] A. Lincoff,et al. Anthracycline-Induced Cardiotoxicity , 1996, Annals of Internal Medicine.
[10] S. Colan,et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.
[11] D. V. Von Hoff,et al. Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.
[12] S. Sternberg,et al. The cardiotoxicity of adriamycin and daunomycin in children , 1976, Cancer.
[13] S. Lipsitz,et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. Steinherz,et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. , 1991, JAMA.
[15] D. Cox. Regression Models and Life-Tables , 1972 .
[16] S. Sallan,et al. Congestive heart failure due to adriamycin cardiotoxicity: Its natural history in children , 1981, Cancer.
[17] J. Silber,et al. Increased risk of cardiac dysfunction after anthracyclines in girls. , 1993, Medical and pediatric oncology.
[18] F. Bu'Lock,et al. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. , 1995, British heart journal.
[19] J. Pitha,et al. A clinicopathologic analysis of adriamycin cardiotoxicity , 1973, Cancer.
[20] A. Evans,et al. Late effects of treatment for wilms' tumor. A report from the national wilms' tumor study group , 1991, Cancer.
[21] E J Orav,et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. , 1995, The New England journal of medicine.